{"id":154864,"date":"2023-01-08T04:24:12","date_gmt":"2023-01-08T10:24:12","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/01\/longevity-biotech-this-is-still-just-the-beginning"},"modified":"2023-01-08T04:24:12","modified_gmt":"2023-01-08T10:24:12","slug":"longevity-biotech-this-is-still-just-the-beginning","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/01\/longevity-biotech-this-is-still-just-the-beginning","title":{"rendered":"Longevity biotech: \u2018This is still just the beginning\u2019"},"content":{"rendered":"

<\/a><\/p>\n

Powered by data produced by its AI-driven discovery platform, clinical-stage biotech BioAge Labs<\/a> is rapidly developing a pipeline of therapies to extend healthy lifespan by targeting the molecular causes of aging. Having raised more than $120 million in funding, and with multiple clinical trials already under its belt, the company is focused on building a broad pipeline of potential longevity therapies in three main areas: muscle, immune, and brain aging.<\/p>\n

Longevity. Technology: There are few companies in the longevity biotech field that appear to be executing on their vision as quickly and consistently as BioAge<\/a>. When the company wowed the sector with a $90 million funding round<\/a> in 2020, talk of multiple imminent clinical trials may have sounded optimistic to some, but BioAge has delivered on its promise time and again. Beyond the trials already underway, the company\u2019s much-vaunted AI discovery platform also appears to be churning out the data, this year spawning a new programme exploring the potential of NLRP3 inhibitors in brain aging. To learn more, we caught up with BioAge co-founder and CEO Kristen Fortney<\/a>.<\/em><\/strong><\/p>\n

Looking back at 2022, Fortney says it has been \u201cimmensely gratifying\u201d to see so many new companies and investors coming into the longevity field.<\/p>\n","protected":false},"excerpt":{"rendered":"

Powered by data produced by its AI-driven discovery platform, clinical-stage biotech BioAge Labs is rapidly developing a pipeline of therapies to extend healthy lifespan by targeting the molecular causes of aging. Having raised more than $120 million in funding, and with multiple clinical trials already under its belt, the company is focused on building a [\u2026]<\/p>\n","protected":false},"author":556,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,269,6],"tags":[],"class_list":["post-154864","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-life-extension","category-robotics-ai"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/154864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=154864"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/154864\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=154864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=154864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=154864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}